ATE126438T1 - Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren. - Google Patents

Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.

Info

Publication number
ATE126438T1
ATE126438T1 AT90112426T AT90112426T ATE126438T1 AT E126438 T1 ATE126438 T1 AT E126438T1 AT 90112426 T AT90112426 T AT 90112426T AT 90112426 T AT90112426 T AT 90112426T AT E126438 T1 ATE126438 T1 AT E126438T1
Authority
AT
Austria
Prior art keywords
salts
folic acid
leucovine
methods
pharmaceutical formulation
Prior art date
Application number
AT90112426T
Other languages
English (en)
Inventor
Bruce Edwin Haeger
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE126438T1 publication Critical patent/ATE126438T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT90112426T 1989-08-21 1990-06-29 Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren. ATE126438T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39657389A 1989-08-21 1989-08-21

Publications (1)

Publication Number Publication Date
ATE126438T1 true ATE126438T1 (de) 1995-09-15

Family

ID=23567787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90112426T ATE126438T1 (de) 1989-08-21 1990-06-29 Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.

Country Status (11)

Country Link
EP (1) EP0416232B1 (de)
JP (1) JP3043381B2 (de)
KR (1) KR0159768B1 (de)
AT (1) ATE126438T1 (de)
AU (1) AU628211B2 (de)
CA (1) CA2023563C (de)
DE (1) DE69021673T2 (de)
DK (1) DK0416232T3 (de)
ES (1) ES2076263T3 (de)
GR (1) GR3017143T3 (de)
PT (1) PT95026B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
CH687062A5 (de) * 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
JP4545632B2 (ja) * 2005-04-25 2010-09-15 株式会社 伊藤園 葉酸含有組成物及び葉酸の安定化方法
JP4919024B2 (ja) * 2006-11-16 2012-04-18 横河電機株式会社 圧力センサ
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
WO2014112392A1 (ja) 2013-01-21 2014-07-24 パナソニック株式会社 赤外線検出素子、赤外線検出器及び赤外線式ガスセンサ
JP6057254B2 (ja) * 2013-01-23 2017-01-11 パナソニックIpマネジメント株式会社 赤外線受光ユニット、赤外線式ガスセンサ
EP2799060A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile hochdosierte pharmazeutische Zusammensetzung enthaltend Levoleucovorin
EP2799061A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile pharmazeutische Hochdosiszusammensetzungen enthaltend Folate
WO2016123076A1 (en) * 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
CN117224478B (zh) * 2023-10-21 2026-02-06 陕西丽彩药业有限公司 一种盐酸乌拉地尔注射液及其制备方法
CN118059042A (zh) * 2024-04-17 2024-05-24 成都瑞尔医药科技有限公司 一种亚叶酸钙注射液及其制备方法
US12564592B1 (en) 2024-12-23 2026-03-03 Riconpharma LLC Injectable leucovorin formulations and methods of preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695860A (en) * 1952-04-29 1954-11-30 American Cyanamid Co Stabilized pteroyl solutions
US4071620A (en) * 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid

Also Published As

Publication number Publication date
EP0416232A3 (en) 1992-01-02
DK0416232T3 (da) 1995-09-18
CA2023563C (en) 2000-02-22
PT95026B (pt) 1997-12-31
DE69021673D1 (de) 1995-09-21
GR3017143T3 (en) 1995-11-30
JPH0390026A (ja) 1991-04-16
KR910004194A (ko) 1991-03-28
ES2076263T3 (es) 1995-11-01
EP0416232A2 (de) 1991-03-13
PT95026A (pt) 1991-04-18
AU628211B2 (en) 1992-09-10
KR0159768B1 (ko) 1998-12-01
JP3043381B2 (ja) 2000-05-22
EP0416232B1 (de) 1995-08-16
DE69021673T2 (de) 1996-05-02
CA2023563A1 (en) 1991-02-22
AU6116590A (en) 1991-02-21

Similar Documents

Publication Publication Date Title
ATE126438T1 (de) Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.
ATE108329T1 (de) Morphin enthaltende zusammensetzung.
DE69516540D1 (de) AMINO-IMIDAZO [4,5-c] CHINOLINE
IT1200589B (it) Derivati naturali attivita farmagologica
FI971486A0 (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
DE69625046D1 (de) Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
NO902488D0 (no) Karboplatinapreparat.
ATE122675T1 (de) Stabile salze von 5,10- methylentetrahydrofolsäure.
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
AR245591A1 (es) Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas.
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
DE59101404D1 (de) Topische Präparate.
DK0553790T3 (da) Cyklisk AMP-derivatholdig salve
DE69000259D1 (de) Pharmazeutische zusammensetzung enthaltend 1-isopropyldihydrolysergsaeure.
ATE91414T1 (de) Hustenstillende zusammensetzungen und ein verfahren zu deren herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time